ASP Isotopes Restarts Si-28 Enrichment Stages, Targets Q3 2026 Shipments

What happened

ASP Isotopes announced engineering enhancements and a successful restart of the first 18 stages of its Silicon-28 enrichment facility, which operated at target levels for over three weeks. The company has three signed commercial contracts for enriched Si-28 and expects initial commercial shipments to begin in Q3 2026, consistent with prior guidance. This operational milestone follows an October 2025 power surge that damaged a laser and halted production, highlighting facility uptime as a key risk. Despite the progress, ASPI reported zero revenue from enriched isotope sales as of March 31, 2026, and continues to burn cash while funding multiple buildouts. The restart is a necessary step, but the investment thesis remains contingent on converting these operational achievements into recognized, repeatable revenue.

Implication

The operational restart is encouraging but does not alter the core thesis: ASPI must demonstrate sustained production and paid shipments to justify its valuation. Investors should monitor Q3 2026 for actual commercial deliveries and subsequent quarterly filings for recognized isotope revenue. Until then, the stock remains a show-me story with execution risk, and the WAIT rating remains appropriate.

Thesis delta

The restart of the Si-28 facility and reaffirmed Q3 2026 shipment target slightly reduces near-term operational risk but does not change the fundamental need to see recognized revenue from enriched isotopes. The thesis remains tied to delivery and cash flow, not just production milestones.